- Home
- RCS vs MGNX Comparison
RCS vs MGNX Comparison
Compare RCS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- MGNX
- Stock Information
- Founded
- RCS 1994
- MGNX 2000
- Country
- RCS United States
- MGNX United States
- Employees
- RCS N/A
- MGNX N/A
- Industry
- RCS Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- MGNX Health Care
- Exchange
- RCS Nasdaq
- MGNX Nasdaq
- Market Cap
- RCS 292.8M
- MGNX 257.3M
- IPO Year
- RCS N/A
- MGNX 2013
- Fundamental
- Price
- RCS $6.54
- MGNX $3.00
- Analyst Decision
- RCS
- MGNX Hold
- Analyst Count
- RCS 0
- MGNX 10
- Target Price
- RCS N/A
- MGNX $7.17
- AVG Volume (30 Days)
- RCS 141.1K
- MGNX 496.5K
- Earning Date
- RCS 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- RCS 10.12%
- MGNX N/A
- EPS Growth
- RCS N/A
- MGNX N/A
- EPS
- RCS N/A
- MGNX N/A
- Revenue
- RCS N/A
- MGNX $141,329,000.00
- Revenue This Year
- RCS N/A
- MGNX $174.73
- Revenue Next Year
- RCS N/A
- MGNX N/A
- P/E Ratio
- RCS N/A
- MGNX N/A
- Revenue Growth
- RCS N/A
- MGNX 16.68
- 52 Week Low
- RCS $4.51
- MGNX $2.91
- 52 Week High
- RCS $6.31
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- RCS 41.39
- MGNX 37.54
- Support Level
- RCS $6.26
- MGNX $3.00
- Resistance Level
- RCS $6.50
- MGNX $3.22
- Average True Range (ATR)
- RCS 0.32
- MGNX 0.17
- MACD
- RCS 0.01
- MGNX -0.02
- Stochastic Oscillator
- RCS 41.35
- MGNX 13.04
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).